USC Research Center for Liver Disease
USC Research Center for Liver Disease
批准号:
9882994
负责人:
Lucy Mary Golden
金额:
$112.71万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-03-01 至 2022-02-28
关键词:
AchievementAcuteAcute Liver FailureAdministratorBiochemistryCell Culture TechniquesCell DeathCell SeparationCellsCellular biologyCirrhosisCollaborationsCore FacilityDevelopmentDevelopmental BiologyDiagnosisDigestive System DisordersDisciplineDiseaseEquipmentFacultyFibrosisFosteringFundingGerontologyGoalsHepatocyteHepatotoxicityHigh Pressure Liquid ChromatographyHistologyHome environmentImmunohistochemistryImmunologyIndividualInflammationInterdisciplinary StudyLaboratoriesLifeLiverLiver diseasesMalignant neoplasm of liverMass Spectrum AnalysisMedicineMetabolicMicrobiologyMicroscopyMitochondriaMolecular BiologyOperative Surgical ProceduresOutcomePathogenesisPathologyPharmacologic SubstancePhilosophyPostdoctoral FellowPreventionPrimary carcinoma of the liver cellsProductivityProteomicsPublic HealthRegenerative MedicineResearchResearch PersonnelScienceServicesStainsSteatohepatitisTalentsTechnologyTissue imagingTrainingUnited States National Institutes of HealthViral hepatitisVisionbasecareer developmentcellular imagingchronic liver diseaseclinical investigationclinical translationcost effectiveeconomic costimaging facilitiesimprovedinnovationinstrumentationinterestliver injurymembernonalcoholic steatohepatitisoperationpediatric pharmacologyproblem drinkerprogramspublic health relevancerepairedspecial interest groupstem cell biologysuccesssymposium
中文摘要
英文摘要
DESCRIPTION, OVERALL (provided by applicant): The USC Research Center for Liver Disease (RCLD), which was founded in 1995, is dedicated to fostering and facilitating the collaborative research of its 57 current members and the career development of junior faculty through provision of research technologies and fora for scientific exchange. Thirty-seven members contribute to a stable research base in excess of ten million dollars annually with a growing translational emphasis. The Specific Aims of the USC Research Center for Liver Disease are: 1) To provide the essential services offered by Biomedical Core facilities to facilitate the research of the membership to advance our understanding of the pathogenesis and treatment of liver and digestive disease; 2) To foster collaboration between Center members through the use of Cores, the enrichment program, and the Special Interest group; 3) To foster career development through availability of Biomedical Cores, enrichment program, and pilot/feasibility support and attract the talents of established investigators from other fields to
apply their expertise to liver and digestive disease research and to collaborate with Center members; 4) Facilitate the technological training and scientific development of postdoctoral fellows, K awardees and junior faculty through the services of the scientific cores, the enrichment program and pilot funding. The RCLD serves as the focal point for the interaction of a large number of faculty conducting research to advance our understating of the pathogenesis, prevention and treatment of liver diseases. The Center focuses on research in Liver Disease with 4 major themes: 1) viral hepatitis and liver cancer, 2) steatohepatitis and fibrosis, 3) hepatotoxicity and mitochondrial pathobiology, 4) repair, regenerative medicine and developmental biology. The Center supports an Administrative Core, the hub for all Center activities, includes the Center Director [Kaplowitz], Associate Director [DeLeve], and Assistant Director [Ookhtens], Administrator [Vidrio], who constitute the Operations Committee, as well as an Executive Committee and External Scientific Advisory Board. The Enrichment Program sponsors seminars, an annual symposium and research mini-symposia. The Pilot/Feasibility Project Program preferentially funds innovative new projects of young investigators which are relevant to the Center's themes. The Center has four scientific Cores: 1) Cell and Tissue Imaging (advanced microscopy), 2) Liver Histology (routine, special stains and immunohistochemistry), 3) Cell Separation and Culture (fluorescent cell sorting and liver cell culture), 4) Analytical (HPLC services), Metabolic (mitochondrial function), Instrumentation (shared central core equipment), and Proteomics Core (mass spectrometry).
期刊论文(290)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/onc.2013.437
发表时间:
2014-10-16
期刊:
Oncogene
影响因子:
8
作者:
[]
通讯作者:
DOI:
10.14309/ctg.0000000000000614
发表时间:
2023-09-01
期刊:
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
影响因子:
3.6
作者:
[Dawit, Lillian, Lee, Vivian, Lehoang, David, Furey, Cameron, Chowdhury, Aneesa, Thu Anne Mai, Angajala, Varun, Park, Joo Hye, Khadarian, Kevork, She, Rosemary, Vergara-Lluri, Maria, Kahn, Jeffrey, Dodge, Jennifer L., Saito, Takeshi]
通讯作者:
Saito, Takeshi
DOI:
10.1007/s12033-011-9422-6
发表时间:
2012-05
期刊:
Molecular biotechnology
影响因子:
2.6
作者:
[Mo RH, Zaro JL, Ou JH, Shen WC]
通讯作者:
Shen WC
DOI:
10.2147/ijn.s53886
发表时间:
2014
期刊:
International journal of nanomedicine
影响因子:
8
作者:
[Shi P, Gustafson JA, MacKay JA]
通讯作者:
MacKay JA
DOI:
10.1016/j.molcel.2017.09.022
发表时间:
2017-10-19
期刊:
Molecular cell
影响因子:
16
作者:
[Liu K, Lee J, Kim JY, Wang L, Tian Y, Chan ST, Cho C, Machida K, Chen D, Ou JJ]
通讯作者:
Ou JJ
共 150 条
Innate Immunity, Cholesterol, and NASH Pathogenesis
-
批准号:10321651
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Lucy Mary Golden
-
依托单位:
Innate Immunity, Cholesterol, and NASH Pathogenesis
-
批准号:10595671
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2020
-
负责人:Lucy Mary Golden
-
依托单位:
Human Group 2 Innate Lymphocyte Cell (ILC2) populations contribute to Hepatic Fibrosis
-
批准号:9288175
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2015
-
负责人:Lucy Mary Golden
-
依托单位:
Human Group 2 Innate Lymphocyte Cell (ILC2) populations contribute to Hepatic Fibrosis
-
批准号:9109629
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2015
-
负责人:Lucy Mary Golden
-
依托单位:
Human Group 2 Innate Lymphocyte Cell (ILC2) populations contribute to Hepatic Fibrosis
-
批准号:8945691
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2015
-
负责人:Lucy Mary Golden
-
依托单位:
海外基金